Protalix BioTherapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Protalix BioTherapeutics has a total shareholder equity of $32.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $61.6M and $29.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$27.41m |
| Equity | US$32.44m |
| Total liabilities | US$29.13m |
| Total assets | US$61.56m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: PLX's short term assets ($47.9M) exceed its short term liabilities ($24.2M).
Long Term Liabilities: PLX's short term assets ($47.9M) exceed its long term liabilities ($4.9M).
Debt to Equity History and Analysis
Debt Level: PLX is debt free.
Reducing Debt: PLX currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable PLX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: PLX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 5.3% per year.